SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001829126-23-004483
Filing Date
2023-06-29
Accepted
2023-06-29 16:15:27
Documents
12
Period of Report
2023-06-29
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K titanpharma_8k.htm   iXBRL 8-K 49817
  Complete submission text file 0001829126-23-004483.txt   224254

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE ttnp-20230629.xsd EX-101.SCH 3021
3 XBRL LABEL FILE ttnp-20230629_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE ttnp-20230629_pre.xml EX-101.PRE 22363
6 EXTRACTED XBRL INSTANCE DOCUMENT titanpharma_8k_htm.xml XML 3338
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

IRS No.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-13341 | Film No.: 231057560
SIC: 2836 Biological Products, (No Diagnostic Substances)